comparemela.com

Latest Breaking News On - Tarun upadhyay - Page 4 : comparemela.com

Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations

RMAT designation intended to help expedite development of new regenerative medicines MALVERN, Pa., Dec. 19, 2023 Ocugen, Inc. , a biotechnology company focused on discovering, developing, and.

United statesTarun upadhyayNuclear hormone receptors nhrsOcugen incHead of communicationsExchange commissionChief scientific officerBest corrected visual acuityLow luminance visual acuityMulti luminance mobility testCentury curesNuclear hormone receptorsPrivate securities litigation reform act

Ocugen, Inc Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

MALVERN, Pa., Dec. 13, 2023 Ocugen, Inc. , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today.

United statesUniversity of arizonaMark kwongTarun upadhyayShankar musunuriBenjamin bakallCollege of medicineOcugen incHead of communicationsExchange commissionNarmada phaseChief scientific officerAssociated retina consultantsOrphan receptorRetina consultantsPrivate securities litigation reform act

Ocugen, Inc (NASDAQ:OCGN) Q3 2023 Earnings Call Transcript

Operator: Good morning and welcome to Ocugen’s Third Quarter 2023 Financial Results and Business Update. Please note that this call is being recorded at this time.

Tarun upadhyayMichael breiningerShankar musunuriHead of researchOcugen incExchange commissionNational institute of allergyOcugen head of corporate communicationsCall transcript novemberThird quarterTiffany hamiltonCorporate controllerChief scientific officerPrivate securities litigation reform actRisk factorsCheap stocks to buy for

Ocugen (OCGN) Q3 2023 Earnings Call Transcript

OCGN earnings call for the period ending September 30, 2023.

United statesTarun upadhyayMichael breiningerShankar musunuriRobert leboyerTiffany hamilton head of corporate communicationsShankar musunuri coExchange commissionNational institute of allergyHead of researchCompany analystTiffany hamiltonMotley fool stock advisorStock advisorPrivate securities litigation reform actRisk factors

Ocugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit

MALVERN, Pa., Nov. 07, 2023 Ocugen, Inc. , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today.

United statesTarun upadhyayTherapeutic drug developmentExchange commissionOcugen incHead of researchTherapeutic development summitHead of communicationsChief scientific officerAnnual dryDevelopment summitDeeper understandingUnderlying causesInform therapeutic drug developmentPrivate securities litigation reform act

vimarsana © 2020. All Rights Reserved.